Skip to main content
Equibles

TLSA · Tiziana Life Sciences Ltd

Track TLSA — free

Use TLSA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TLSA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.01 +0.00 (+0.00%) At close · Oct 21
Rebalance outlook locked
Market Cap
$127.26M
Shares
127.26M
Volume · Oct 21 421.48K Avg daily vol (3M) 761.6K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.01 Open$1.03 Day$0.97–1.03 52W close$0.77–1.95 Avg vol 30d660K Short int2.6M · 2.1% float · 3.2d Short vol34% DataJan 2020–Oct 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+8.1%
Year over year · more shares
Price change (1Y)
-48.5%
Trailing year
Short interest
2.1%
Latest settlement · 3.2 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 17.3 · elevated Equity put/call 0.56
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −18%
below
Price vs 50-day avg −2%
below
RSI (14) 46
neutral
MACD trend Negative
52-week position 20%
mid-range
Momentum
relative strength
Very Weak
1-month return −4%
trailing
6-month return −21%
trailing
YTD return −32%
this year
Relative strength −29%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
3 of 31 funds reported for Sep 30 · net +10.1K sh shares · +1 new
Insider flow Accumulating
Net +$985.9K over 90 days · 0% sells
Short interest Rising
2.08% of float · ▲ +52.3% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
31 holders — mid 3-yr range
Squeeze score 62
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 81%
annualized · 1-yr
Max drawdown −61%
past year
ATR 8.2%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−18% Bearish
Price vs 50-day avg
−2% Neutral
RSI (14)
46 Neutral
MACD trend
Negative Bearish
52-week position
20% Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
3 of 31 funds reported for Sep 30 · net +10.1K sh shares · +1 new
Insider flow Accumulating
Net +$985.9K over 90 days · 0% sells
Short interest Rising
2.08% of float · ▲ +52.3% MoM · 3.2 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
31 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $1 · 20% Range high $2
vs 200-day avg -18% vs 50-day avg -2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TLSA
Tiziana Life Sciences Ltd
this stock
$127.26M -32.2% — — 2.1%
VRTX
Vertex Pharmaceuticals Inc
 $131.39B +15.7% +46.2% 30.2 1.8%
MRNA
Moderna, Inc.
 $96.65B +733.5% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.13B +4.4% +20.8% 20.0 2.1%
CSLLY
Csl Ltd
 $66.22B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
32
% held
2.0%
Reported
3 of 31
Top holder
Dauntless Investment Grou…
Held Float
View
Short & Settlement
Short Interest Rising
Shares short
2.6M
Days to cover
3.2d
Change
+906.9K sh
View
Short Volume
Short vol %
34%
As of
Oct 21, 2026
Short Total
View
Fails to Deliver
FTD shares
738
Value
$701
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
51.2%
Week of
Sep 14, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net buying
Net (90d)
+$985.9K
Buyers / Sellers
1 / 0
Buyers Sellers
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 21, 2026
This year
28

Tiziana Life Sciences said 14 patients with na-SPMS dosed with intranasal foralumab showed improvement or stability within 6 months; its team will attend MSToronto2026, held October 21–23, 2026.

View
Earnings & Events
Investor Relations
Latest news
Tiziana Doses Last Patient in Pha…
Published
Oct 16, 2026
View

Performance

5D 20D 120D MTD YTD
TLSA -3.8% -3.8% -21.1% -9.0% -32.2%
SPY +0.5% +0.7% +7.6% +1.4% +13.4%
vs SPY -4.3% -4.5% -28.7% -10.4% -45.6%
Key facts CIK 1723069 CUSIP G88912103 13F (30d) 3 filings 3 filers Visit website Investor relations